The role of clinical nonfatal end points in cardiovascular phase II/III clinical trials.
O'Connor
C M
CM
Duke University Medical Center, Durham, NC 27710, USA.
Gattis
W A
WA
Ryan
T J
TJ
D002317:Cardiovascular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic / Q000706:statistics & numerical data*; D017326:Clinical Trials, Phase III as Topic / Q000706:statistics & numerical data*; D006801:Humans; D015203:Reproducibility of Results; D016019:Survival Analysis; D016896:Treatment Outcome
D002317:Cardiovascular Agents